<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.0 20120330//EN" "JATS-archivearticle1.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">Can J Kidney Health Dis</journal-id><journal-id journal-id-type="iso-abbrev">Can J Kidney Health Dis</journal-id><journal-title-group><journal-title>Canadian Journal of Kidney Health and Disease</journal-title></journal-title-group><issn pub-type="epub">2054-3581</issn><publisher><publisher-name>BioMed Central</publisher-name><publisher-loc>London</publisher-loc></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">26038709</article-id><article-id pub-id-type="pmc">4452142</article-id><article-id pub-id-type="publisher-id">15</article-id><article-id pub-id-type="doi">10.1186/2054-3581-1-16</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research</subject></subj-group></article-categories><title-group><article-title>Cardiac biomarkers and health-related quality of life in new hemodialysis patients without symptomatic cardiac disease</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Williams</surname><given-names>Christopher E</given-names></name><address><email>cew660@mun.ca</email></address><xref ref-type="aff" rid="Aff1"/></contrib><contrib contrib-type="author"><name><surname>Curtis</surname><given-names>Bryan M</given-names></name><address><email>bcurtis@mun.ca</email></address><xref ref-type="aff" rid="Aff1"/></contrib><contrib contrib-type="author"><name><surname>Randell</surname><given-names>Edward W</given-names></name><address><email>ed.randell@easternhealth.ca</email></address><xref ref-type="aff" rid="Aff2"/></contrib><contrib contrib-type="author"><name><surname>Foley</surname><given-names>Robert N</given-names></name><address><email>rfoley@mun.ca</email></address><xref ref-type="aff" rid="Aff3"/></contrib><contrib contrib-type="author" corresp="yes"><name><surname>Parfrey</surname><given-names>Patrick S</given-names></name><address><email>pparfrey@mun.ca</email></address><xref ref-type="aff" rid="Aff1"/></contrib><aff id="Aff1"><label/>Division of Nephrology, Health Sciences Center, Memorial University, St. John&#x02019;s, Newfoundland A1B 3&#x000a0;V6 Canada </aff><aff id="Aff2"><label/>Laboratory Medicine, Faculty of Medicine, Memorial University, St. John&#x02019;s, Newfoundland Canada </aff><aff id="Aff3"><label/>Chronic Disease Research Group, University of Minnesota, Minneapolis, MA USA </aff></contrib-group><pub-date pub-type="epub"><day>15</day><month>7</month><year>2014</year></pub-date><pub-date pub-type="pmc-release"><day>15</day><month>7</month><year>2014</year></pub-date><pub-date pub-type="collection"><year>2014</year></pub-date><volume>1</volume><elocation-id>16</elocation-id><history><date date-type="received"><day>20</day><month>3</month><year>2014</year></date><date date-type="accepted"><day>20</day><month>6</month><year>2014</year></date></history><permissions><copyright-statement>&#x000a9; Williams et al.; licensee BioMed Central Ltd. 2014</copyright-statement><license license-type="open-access"><license-p>This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0">http://creativecommons.org/licenses/by/4.0</ext-link>), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited. The Creative Commons Public Domain Dedication waiver (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/publicdomain/zero/1.0/">http://creativecommons.org/publicdomain/zero/1.0/</ext-link>) applies to the data made available in this article, unless otherwise stated.</license-p></license></permissions><abstract id="Abs1"><sec><title>Background</title><p>Health Related Quality of Life (HRQOL) is impaired in hemodialysis patients and cardiac biomarkers are elevated, but their relationship is uncertain.</p></sec><sec><title>Objectives</title><p>To determine whether the cardiac biomarkers, troponin T and N terminal pro-B type natriuretic peptide (NT-proBNP), predict deterioration in the physical domains of HRQOL.</p></sec><sec><title>Design</title><p>A prospective cohort study of patients in a randomized controlled clinical trial of correction of anemia with erythropoietin.</p></sec><sec><title>Setting</title><p>Multiple hemodialysis centers located throughout Canada and Europe.</p></sec><sec><title>Participants</title><p>Patients who started maintenance hemodialysis within the previous 3&#x02013;18 months, with no clinical evidence or prior history of symptomatic cardiac failure or ischemic heart disease, and left ventricular volume&#x02009;&#x0003c;&#x02009;100&#x000a0;ml/m<sup>2</sup>.</p></sec><sec><title>Measurements</title><p><italic>Predictor</italic>: Baseline concentrations of Troponin T and NT-proBNP. <italic>Outcomes</italic>: Physical function and vitality scores using the SF-36 questionnaire and fatigue scores using the FACIT questionnaire at baseline and after 24, 48, and 96&#x000a0;weeks follow-up.</p></sec><sec><title>Methods</title><p>Univariate analysis of the association between baseline variables and baseline HRQOL scores and change in scores over time was undertaken using linear regression. Multivariate models were created using multiple linear regression, and it was pre-specified that these include the variables which were associated with the outcome at a p&#x02009;&#x0003c;&#x02009;0.05 in the univariate regression.</p></sec><sec><title>Results</title><p>Baseline median (interquartile range) physical function score was 70 (50&#x02013;85), vitality 55 (40&#x02013;75), and fatigue 73 (58&#x02013;86). The 75th percentile for Troponin T was 0.05&#x000a0;ng/mL and for NT-proBNP 652&#x000a0;ng/mL. High Troponin T levels were significantly associated with deterioration in the 3 physical domains, independent of other risk factors, whereas high NT-proBNP were not associated. In multivariate models baseline Troponin T&#x02009;&#x0003e;&#x02009;0.05&#x000a0;ng/mL were significantly associated with the change from baseline to 96&#x000a0;weeks follow-up for SF-36 vitality and FACIT-fatigue scores, and approached statistical significance for SF-36 physical function (0.056).</p></sec><sec><title>Limitations</title><p>Not possible to confirm whether Troponin T associations were independent of subsequent cardiac events.</p></sec><sec><title>Conclusions</title><p>In hemodialysis patients without prior symptomatic cardiac disease and without a dilated left ventricle at baseline, elevated baseline Troponin T levels, but not NT-pro BNP, were independently associated with deterioration in the physical domains of HRQOL.</p></sec><sec><title>Electronic supplementary material</title><p>The online version of this article (doi:10.1186/2054-3581-1-16) contains supplementary material, which is available to authorized users.</p></sec></abstract><trans-abstract xml:lang="fr" id="Abs2"><title>Abr&#x000e9;g&#x000e9;</title><sec><title>Contexte</title><p>Chez les patients en h&#x000e9;modialyse, la qualit&#x000e9; de vie li&#x000e9;e &#x000e0; la sant&#x000e9; (QVLS) est diminu&#x000e9;e, et les biomarqueurs cardiaques sont &#x000e9;lev&#x000e9;s, mais la relation entre les deux est incertaine.</p></sec><sec><title>Objectifs</title><p>D&#x000e9;terminer si les biomarquers cardiaques, la troponine T et le N-terminal peptide natriur&#x000e9;tique de type B (NT-ProBNP), pr&#x000e9;disent la d&#x000e9;t&#x000e9;rioration des domaines physiques de la QVLS.</p></sec><sec><title>Type d&#x02019;&#x000e9;tude</title><p>Une &#x000e9;tude prospective de cohorte sur des patients dans le cadre d&#x02019;un essai clinique contr&#x000f4;l&#x000e9; randomis&#x000e9; concernant la correction de l&#x02019;an&#x000e9;mie &#x000e0; l&#x02019;aide de l&#x02019;&#x000e9;rythropo&#x000ef;&#x000e9;tine.</p></sec><sec><title>Contexte</title><p>Plusieurs centres d&#x02019;h&#x000e9;modialyse situ&#x000e9;s au Canada et en Europe, coordonn&#x000e9;s de fa&#x000e7;on centralis&#x000e9;e &#x000e0; partir de St. John&#x02019;s, au Canada, pour les patients canadiens, et de Manchester, en Angleterre, pour les patients europ&#x000e9;ens.</p></sec><sec><title>Participants</title><p>Les patients en h&#x000e9;modialyse chronique de plusieurs centres, qui ont entam&#x000e9; une dialyse au cours des derniers 3 &#x000e0; 18 mois, et qui ne pr&#x000e9;sentent aucune donn&#x000e9;e clinique et aucun ant&#x000e9;c&#x000e9;dent d&#x02019;insuffisance cardiaque symptomatique ou de cardiopathie isch&#x000e9;mique, mais un volume ventriculaire gauche&#x02009;&#x0003c;&#x02009;100 ml/m<sup>2</sup>.</p></sec><sec><title>Mesures</title><p><italic>Pr&#x000e9;dicteur</italic>: concentration de r&#x000e9;f&#x000e9;rence de Troponine T et de NT-proBNP. <italic>R&#x000e9;sultats:</italic> Degr&#x000e9; de vitalit&#x000e9; et fonction physique &#x000e0; l&#x02019;aide du questionnaire SF-36 et degr&#x000e9; de fatigue &#x000e0; l&#x02019;aide du questionnaire FACIT, au point de r&#x000e9;f&#x000e9;rence, puis apr&#x000e8;s le suivi des 24, 48 et 96 semaines.</p></sec><sec><title>M&#x000e9;thodes</title><p>L&#x02019;analyse unidimensionnelle de l&#x02019;association entre les variables fondamentales et les scores de r&#x000e9;f&#x000e9;rence de la QVLS, et la variation dans les scores a &#x000e9;t&#x000e9; entreprise au moyen de la r&#x000e9;gression lin&#x000e9;aire. Les mod&#x000e8;les multivariables ont &#x000e9;t&#x000e9; cr&#x000e9;&#x000e9;s en utilisant la r&#x000e9;gression lin&#x000e9;aire multiple, et il a &#x000e9;t&#x000e9; pr&#x000e9;-sp&#x000e9;cifi&#x000e9; que ceux-ci comprenaient les variables associ&#x000e9;es aux r&#x000e9;sultats de p&#x02009;&#x0003c;&#x02009;0,05 dans la r&#x000e9;gression &#x000e0; une variable.</p></sec><sec><title>R&#x000e9;sultats</title><p>Le score m&#x000e9;dian de r&#x000e9;f&#x000e9;rence (&#x000e9;cart interquartile) de la fonction physique &#x000e9;tait de 70 (50&#x02013;85), celui de la vitalit&#x000e9; de 55 (40&#x02013;75), et celui de la fatigue 73 (58&#x02013;86). Le 75<sup>e</sup> percentile de la troponine T &#x000e9;tait de 0,05 ng/mL, et pour le NT-proBNP, de 652 ng/mL. Les niveaux &#x000e9;lev&#x000e9;s de troponine T &#x000e9;taient associ&#x000e9;s de fa&#x000e7;on significative &#x000e0; la d&#x000e9;t&#x000e9;rioration des 3 domaines physiques, ind&#x000e9;pendants des autres facteurs de risque, alors que les niveaux &#x000e9;lev&#x000e9;s de NT-proBNP ne d&#x000e9;montraient aucune association significative. Dans les mod&#x000e8;les multivariables, un niveau fondamental de troponine T&#x02009;&#x0003e;&#x02009;0,05 ng/mL &#x000e9;tait associ&#x000e9; de fa&#x000e7;on significative &#x000e0; la variation entre le point de r&#x000e9;f&#x000e9;rence et le suivi des 96 semaines en ce qui a trait aux scores SF-36 de vitalit&#x000e9; et FACIT de fatigue, et avaient une certaine signification statistique &#x000e0; une fonction physique de SF-36 (0,056).</p></sec><sec><title>Limites de l&#x02019;&#x000e9;tude</title><p>Impossible de confirmer si les associations avec la troponine T &#x000e9;taient ind&#x000e9;pendantes d&#x02019;&#x000e9;v&#x000e9;nements cardiaques subs&#x000e9;quents.</p></sec><sec><title>Conclusions</title><p>Chez les patients en h&#x000e9;modialyse ne pr&#x000e9;sentant pas d&#x02019;ant&#x000e9;c&#x000e9;dents de maladie cardiaque symptomatique ni une dilatation du ventricule gauche au point de r&#x000e9;f&#x000e9;rence, des niveaux &#x000e9;lev&#x000e9;s de troponine T au point de r&#x000e9;f&#x000e9;rence, mais pas de NT-proBNP, ont &#x000e9;t&#x000e9; ind&#x000e9;pendamment associ&#x000e9;s &#x000e0; une d&#x000e9;t&#x000e9;rioration des domaines physiques de QVLS.</p></sec><sec><title>Trial registration</title><p>Clinical trials.gov #
<ext-link ext-link-type="uri" xlink:href="http://clinicaltrials.gov/ct2/show/NCT00261521">NCT00261521</ext-link>.</p></sec><sec><title>Electronic supplementary material</title><p>The online version of this article (doi:10.1186/2054-3581-1-16) contains supplementary material, which is available to authorized users.</p></sec></trans-abstract><custom-meta-group><custom-meta><meta-name>issue-copyright-statement</meta-name><meta-value>&#x000a9; The Author(s) 2014</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="Sec1"><title>What was known before</title><p>Patients with ESRD have diminished scores in the physical domains of health related quality of life. Biomarkers for adequacy of dialysis, mineral metabolism and inflammation correlate poorly with these domains, although nutritional biomarkers do correlate.</p></sec><sec id="Sec2"><title>What the study adds</title><p>In hemodialysis patients without prior symptomatic cardiac disease elevated baseline Troponin T levels, but not B type natriuretic peptide, are associated with deterioration in the physical domains of quality of life.</p></sec><sec id="Sec3"><title>Background</title><p>Health Related Quality of Life (HRQOL) is a consistent predictor of mortality in end stage renal disease (ESRD) (
[<xref ref-type="bibr" rid="CR1">1</xref>&#x02013;<xref ref-type="bibr" rid="CR3">3</xref>]). Patients with ESRD have consistently diminished HRQOL compared with matched controls without ESRD, most pronounced in physical function and vitality (
[<xref ref-type="bibr" rid="CR4">4</xref>]). Biomarkers are regularly tracked in dialysis units, but biomarkers for adequacy of dialysis (KT/V), mineral metabolism and inflammation correlate poorly with HRQOL, although nutritional biomarkers associate with the physical domains in HRQOL (
[<xref ref-type="bibr" rid="CR4">4</xref>]). Although HRQOL scores are substantially higher in hemodialysis (HD) patients without prior symptomatic cardiac disease compared to unselected hemodialysis patients (
[<xref ref-type="bibr" rid="CR5">5</xref>, <xref ref-type="bibr" rid="CR6">6</xref>]) the relationship between cardiac biomarkers, such as N terminal pro-B type naturetic peptide (NT-proBNP) and troponin T, and HRQOL is uncertain.</p><p>Cardiovascular events, particularly heart failure and atherosclerotic events have a major impact on HRQOL in ESRD (
[<xref ref-type="bibr" rid="CR7">7</xref>]). Hemodialysis patients who have not experienced these events may have elevated troponin T, a marker of myocardial injury, or elevated NT-proBNP, a marker of left ventricular (LV) wall stress (
[<xref ref-type="bibr" rid="CR8">8</xref>]). To determine whether these cardiac biomarkers associate with poor HRQOL or predict deterioration in HRQOL we analyzed troponin T and NT-proBNP levels in incident HD patients, without prior cardiac failure or ischemic heart disease events and without overt cardiac dilation (N&#x02009;=&#x02009;596), followed for 2&#x000a0;years in a multinational, blinded, randomized controlled trial (
[<xref ref-type="bibr" rid="CR8">8</xref>, <xref ref-type="bibr" rid="CR9">9</xref>]), in whom HRQOL was measured at baseline and serially during follow-up using the SF-36 and FACIT fatigue questionnaires (
[<xref ref-type="bibr" rid="CR5">5</xref>]).</p><p>We hypothesized that cardiac biomarkers would predict deterioration in the physical domains of HRQOL, independent of other baseline clinical characteristics. The objectives of this report are to quantify the associations between traditional biomarkers and cardiac biomarkers, measured at baseline in incident HD patients without symptomatic cardiac disease, and baseline measures of physical function, vitality, and fatigue, together with short-term (24&#x000a0;weeks) and long-term (1 and 2&#x000a0;years) changes in these domains.</p></sec><sec id="Sec4" sec-type="methods"><title>Methods</title><p>The cohort studied in this paper was enrolled in a randomized trial of correction of anemia with erythropoietin (
[<xref ref-type="bibr" rid="CR9">9</xref>]). The design, methods, randomization, and epoetin dosing protocols have been reported previously (
[<xref ref-type="bibr" rid="CR9">9</xref>]). Patients were randomly assigned to one of the following hemoglobin (Hb) targets: 9.5 to 11.5 (low target) or 13.5 to 14.5&#x000a0;g/dl (high target). Patients were masked to treatment assignment, as were their doctors. Mean Hb levels at the end of the initial 24-week titration phase were 13.3 and 10.9&#x000a0;g/dl, respectively. During the maintenance phase, from weeks 24 through 96, corresponding mean Hb levels were 13.1 and 10.8&#x000a0;g/dl. Cardiac structure constituted the primary study outcome, and no difference was observed between the two groups (
[<xref ref-type="bibr" rid="CR9">9</xref>]). Consequently, for the purpose of this article, all patients were included as one cohort. The study was centrally coordinated from St. John&#x02019;s, Canada, for Canadian patients and Manchester, England, For European patients.</p><p>Local independent ethics committees or institutional review boards approved the study protocol form before study initiation. The study was conducted in accordance with Good Clinical Practice guidelines and the Declaration of Helsinki. All patients gave informed consent before study enrollment.</p><sec id="Sec5"><title>Study population</title><p>Inclusion criteria were as follows: Age&#x02009;&#x02265;&#x02009;18&#x000a0;years; inception of maintenance HD within the previous 3 to 18&#x000a0;months; predialysis Hb level between 8 and 12&#x000a0;g/dl; LV volume index (LVVI)&#x02009;&#x0003c;&#x02009;100&#x000a0;ml/m<sup>2</sup>, and predialysis diastolic BP (DBP)&#x02009;&#x0003c;&#x02009;100&#x000a0;mmHg. Exclusion criteria were as follows: Clinical evidence or history of symptomatic cardiac failure or ischemic heart disease; daily prednisone dosages&#x02009;&#x02265;&#x02009;10&#x000a0;mg; medical conditions that are likely to reduce epoetin responsiveness, including uncorrected iron deficiency; concurrent malignancy; blood transfusion in the preceding month; therapy with cytotoxic agents; seizure in the preceding year; hypersensitivity to intravenous iron; and current pregnancy or breastfeeding.</p></sec><sec id="Sec6"><title>Description of study procedures</title><p>Laboratory tests were measured centrally by Quest Diagnostics (Van Nuys, CA, and Heston, UK). With the high target, the treatment goal was increments of 0.5 to 1.0&#x000a0;g/dl every 2&#x000a0;weeks, until achieving stability between 13.5 and 14.5&#x000a0;g/dl. Other treatment goals included predialysis diastolic blood pressure between 70 and 90&#x000a0;mmHg, urea reduction ratio&#x02009;&#x0003e;&#x02009;67%, and transferrin saturation&#x02009;&#x02265;&#x02009;20%. On a weekly basis, midweek predialysis blood pressure levels were communicated weekly to and treatment recommendations sent from the coordinating center. These were determined by the protocols in use at the individual treating centers, and a single, formal, standardized method was not imposed. The last patient completed the study in May 2003.</p><p>Quality of life was assessed using the KDQOL and FACIT fatigue questionnaires (
[<xref ref-type="bibr" rid="CR10">10</xref>, <xref ref-type="bibr" rid="CR11">11</xref>]). We pre-specified the domains of HRQOL for this analysis: physical function and vitality measured using the SF-36 questionnaire and fatigue using the FACIT fatigue questionnaire. Higher scores reflect better health. These were also the pre-specified domains for HRQOL outcomes in the trial (
[<xref ref-type="bibr" rid="CR5">5</xref>]). A-priori we defined short-term change in HRQOL as the change from baseline to the assessment at 24&#x000a0;weeks, and long-term change as the change from baseline to the assessments made at 48 and 96&#x000a0;weeks.</p><p>There was no difference in the clinical or demographic characteristics or in treatment assignment of those who had only one KDQOL assessment n&#x02009;=&#x02009;(
[<xref ref-type="bibr" rid="CR12">12</xref>]) and those who had serial assessments (n&#x02009;=&#x02009;484). At each assessment, &#x0003e; 90% of patients remaining in the study completed the questionnaire.</p></sec><sec id="Sec7"><title>Sample size estimate</title><p>The sample size needed to detect a 15% difference between treatment groups in the primary outcome (left ventricular cavity volume index) was calculated as 166 per treatment group, given a two-tailed significance of 0.05, a power of 0.90, and an SD of the percentage change in left ventricular cavity volume index of 42% (
[<xref ref-type="bibr" rid="CR9">9</xref>]). With an expected dropout rate of 40%, primarily as a result of transplantation, 277 patients were required for each treatment group.</p><p>At baseline SF-36 was completed in 457 patients and FACIT fatigue in 572 patients. The comparable numbers at 24&#x000a0;weeks were 443 and 499, at 48&#x000a0;weeks 435 and 432, and at 96&#x000a0;weeks 335 and 325.</p></sec><sec id="Sec8"><title>Risk factors</title><p>In addition to demographic factors (age, gender, and race), baseline clinical characteristics (diabetes, primary renal disease, dialysis vintage, blood pressure, body mass index, type of vascular access) were recorded, as were conventional laboratory tests results (Hb, white cell count, percentage of iron saturation, urea reduction ratio, and serum albumin) and other serologic tests at baseline. Serum concentrations of N terminal pro-B type natriuretic peptide (NT-proBNP) and cardiac troponin T were measured in 2009 using diagnostic kits and performed on an Elecsys 2010 immunochemistry analyzer (Roche Diagnostics, Montreal, Quebec, Canada). Serum high-sensitivity C-reactive protein was measured using CRP reagent (Beckman Coulter, Fullerton, CA) and performed on an IMMAGE Immunochemistry system (Beckman Coulter). Serum IL-6 was measured using IL-6 kits and performed on a Unicel DxI 800 Access Immunoassay system (Beckman Coulter). Serum leptin was measured by ELISA technique using kits purchased from Diagnostic Systems Laboratories, Inc (Webster, Tx).</p></sec><sec id="Sec9"><title>Statistical analysis</title><p>Baseline characteristics were described by number (%) or by median with interquartile range. For the cardiac and inflammatory biomarkers high levels were pre-specified as above the 75th percentile. Univariate analysis of the association between baseline variables and baseline HRQOL scores and change in scores over time was undertaken using linear regression. Multivariate models were created using multiple linear regression, and it was pre-specified that these include the variables which were associated with the outcome at a p&#x02009;&#x0003c;&#x02009;0.05 in the univariate regression. In addition multivariate models were created to determine the effect of troponin T levels on change in HRQOL independent of age, sex, diabetes and baseline HRQOL score.</p></sec></sec><sec id="Sec10" sec-type="results"><title>Results</title><p>A total of 596 patients were enrolled in 95 treatment centers in 10 countries between February 2000 and June 2001. Table&#x000a0;
<xref rid="Tab1" ref-type="table">1</xref> shows baseline characteristics. Median age was 51.5&#x000a0;years, 39.6% were female, and the vast majority were white. Only 17.8% had diabetes as the cause of ESRD, and patients with a clinical history of cardiac failure and ischemic heart disease were excluded. Incident patients who started dialysis between 3 and 18&#x000a0;months before study entry were enrolled, and median time on dialysis was 9&#x000a0;months. The vast majority (84.2%) had a fistula as vascular access. The distribution of troponin T and for NT-proBNP at baseline is displayed in Figure&#x000a0;
<xref rid="Fig1" ref-type="fig">1</xref> A and B. The upper quartile for troponin T was&#x02009;&#x0003e;&#x02009;0.051&#x000a0;ng/ml (N&#x02009;=&#x02009;118), and for NT-proBNP it was&#x02009;&#x0003e;&#x02009;652&#x000a0;pg/ml (N&#x02009;=&#x02009;120).<table-wrap id="Tab1"><label>Table 1</label><caption><p>
<bold>Baseline demographic and clinical characteristics, biomarkers and HRQOL scores</bold>
</p></caption><table frame="hsides" rules="groups"><tbody><tr><td>Age (yrs); median (25th to 75th percentiles)</td><td>51.5 (39 to 62)</td></tr><tr><td>Female; N (%)</td><td>236 (39.6)</td></tr><tr><td>Non-white race; N (%)</td><td>63 (10.6)</td></tr><tr><td>Cause of ESRD:</td><td/></tr><tr><td>&#x02003;Glomerulonephritis; N (%)</td><td>171 (28.7)</td></tr><tr><td>&#x02003;Diabetic Nephropathy; N (%)</td><td>106 (17.8)</td></tr><tr><td>&#x02003;Polycistic kidney disease; N (%)</td><td>54 (9.1)</td></tr><tr><td>&#x02003;Hypertension; N (%)</td><td>48 (8.1)</td></tr><tr><td>&#x02003;Other/Unknown; N (%)</td><td>217 (36.4)</td></tr><tr><td>Dialysis duration (mo); median (25th to 75th percentiles)</td><td>9 (6 to 14)</td></tr><tr><td>Dialysis access:</td><td/></tr><tr><td>&#x02003;Fistula; N (%)</td><td>502 (84.2)</td></tr><tr><td>&#x02003;Graft; N (%)</td><td>33 (5.5)</td></tr><tr><td>&#x02003;Catheter; N (%)</td><td>61 (10.2)</td></tr><tr><td>Assigned to high Hb target; N (%)</td><td>296 (49.7)</td></tr><tr><td>Epoetin dosage (U/wk); median (25th to 75th percentiles); n&#x02009;=&#x02009;584</td><td>6000 (4000 to 8000)</td></tr><tr><td>BMI (kg/m<sup>2</sup>); median (25th to 75th percentiles)</td><td>25.5 (22.6 to 29.3)</td></tr><tr><td>Systolic BP (mmHg); median (25th to 75th percentiles); n&#x02009;=&#x02009;595</td><td>140 (130 to 158)</td></tr><tr><td>Diastolic BP (mmHg); median (25th to 75th percentiles); n&#x02009;=&#x02009;596</td><td>80 (71 to 90)</td></tr><tr><td>Hemoglobin (g/dl); median (25th to 75th percentiles); n&#x02009;=&#x02009;580</td><td>11 (10.2 to 11.7)</td></tr><tr><td>Serum albumin (g/L); median (25th to 75th percentiles); n&#x02009;=&#x02009;588</td><td>40 (38 to 41)</td></tr><tr><td>Urea reduction ratio (%); median (25th to 75th percentiles); n&#x02009;=&#x02009;572</td><td>67 (60 to 72.5)</td></tr><tr><td>Biomarkers; median (25th to 75th percentiles)</td><td/></tr><tr><td>Cardiac: Troponin T (ng/ml); n&#x02009;=&#x02009;481</td><td>0.021 (0.009 to 0.051)</td></tr><tr><td>NT-proBNP (pg/ml); n&#x02009;=&#x02009;481</td><td>289.2 (137.3 to 651.9)</td></tr><tr><td>Inflammatory: C-Reactive protein (mg/L); n&#x02009;=&#x02009;481</td><td>3.47 (1.47 to 8.13)</td></tr><tr><td>IL-6 (pg/ml); n&#x02009;=&#x02009;481</td><td>4.39 (2.69 to 8.8)</td></tr><tr><td>Leptin (ng/ml); n&#x02009;=&#x02009;481</td><td>12.4 (3.7 to 43.8)</td></tr><tr><td>Quality of life domains; median (25th to 75th percentiles)</td><td/></tr><tr><td>SF-36 Physical functioning; n&#x02009;=&#x02009;457</td><td>70 (50 to 85)</td></tr><tr><td>SF-36 Vitality; n&#x02009;=&#x02009;457</td><td>55 (40 to 75)</td></tr><tr><td>FACIT Fatigue; n&#x02009;=&#x02009;572</td><td>73.1 (57.7 to 86.3)</td></tr></tbody></table></table-wrap><fig id="Fig1"><label>Figure 1</label><caption><p>
<bold>Distribution of baseline troponin T levels (A) and NT-proBNP (B) levels in hemodialysis patients without prior symptomatic cardiac disease.</bold> Troponin T levels are expressed in units of ng/mL and NT-proBNP in units of pg/mL).</p></caption><graphic xlink:href="40697_2014_15_Fig1_HTML" id="d30e742"/></fig></p><sec id="Sec11"><title>Serial HRQOL scores</title><p>Median score for SF-36 physical function was 70, for SF-36 vitality it was 55, and for FACIT fatigue 73 (Table&#x000a0;
<xref rid="Tab1" ref-type="table">1</xref>). Figure&#x000a0;
<xref rid="Fig2" ref-type="fig">2</xref> shows the median scores at baseline, 24, 48, and 96&#x000a0;weeks for the cohort.<fig id="Fig2"><label>Figure 2</label><caption><p>
<bold>Serial HRQOL scores for SF-36 domains physical function and vitality, and for FACIT fatigue, in hemodialysis patients without symptomatic cardiac disease.</bold>
</p></caption><graphic xlink:href="40697_2014_15_Fig2_HTML" id="d30e765"/></fig></p></sec><sec id="Sec12"><title>Associations with baseline HRQOL scores</title><p>Table&#x000a0;
<xref rid="Tab2" ref-type="table">2</xref> shows the significant univariate associations between baseline clinical variables and biomarkers with HRQOL scores. Multivariate models revealed that the significant, independent variables associated with better SF-36 physical function were younger age, presence of a fistula, and lower NT-proBNP. For higher SF-36 vitality and FACIT fatigue scores only higher URR was identified as a significant predictor (Table&#x000a0;
<xref rid="Tab2" ref-type="table">2</xref>). Additional file
<xref rid="MOESM1" ref-type="media">1</xref>: Table S1 shows the results of analysis of the other SF-36 domains, which were not pre-specified.<table-wrap id="Tab2"><label>Table 2</label><caption><p>
<bold>Significant associations between baseline clinical variables and biomarkers and baseline HRQOL scores, using univariate and multivariate analysis</bold>
</p></caption><table frame="hsides" rules="groups"><thead><tr><th>Characteristic</th><th>Reference</th><th>Unadjusted B coefficient</th><th>95% C.I.</th><th>Adjusted B coefficient</th><th>95% C.I.</th></tr></thead><tbody><tr><td colspan="6">
<bold>SF-36 Physical functioning</bold>
</td></tr><tr><td>&#x02003;Female</td><td>Male</td><td>-7.56</td><td>-12.30 to -2.81**</td><td/><td/></tr><tr><td>&#x02003;Age</td><td>Per 1&#x000a0;year</td><td>-0.49</td><td>-0.63 to -0.35**</td><td>-0.38</td><td>-0.56 to -0.20**</td></tr><tr><td>&#x02003;Body Mass Index</td><td>Per 1&#x000a0;kg/m<sup>2</sup>
</td><td>-0.63</td><td>-1.05 to -0.20**</td><td/><td/></tr><tr><td>&#x02003;Diabetes</td><td>No Diabetes</td><td>-8.25</td><td>-14.27 to -2.23**</td><td/><td/></tr><tr><td>&#x02003;Fistula</td><td>No Fistula</td><td>12.52</td><td>6.54 to 18.51**</td><td>10.69</td><td>3.52 to 17.86**</td></tr><tr><td>&#x02003;Serum Albumin</td><td>&#x02264; 40&#x000a0;g/L</td><td>6.36</td><td>1.54 to 11.18**</td><td/><td/></tr><tr><td>&#x02003;Serum Creatinine</td><td>Per 1 umol/L</td><td>0.02</td><td>0.01 to 0.03**</td><td/><td/></tr><tr><td>&#x02003;Sodium</td><td>Per 1&#x000a0;mmol/L</td><td>0.76</td><td>0.06 to 1.46*</td><td/><td/></tr><tr><td>&#x02003;White Blood Cells</td><td>&#x02264; 8.1 &#x000d7; 10<sup>9</sup>/L</td><td>-7.98</td><td>-13.60 to -2.37**</td><td/><td/></tr><tr><td>&#x02003;Neutrophils</td><td>&#x02264; 68%</td><td>-7.33</td><td>-12.90 to -1.77**</td><td/><td/></tr><tr><td>&#x02003;Leptin</td><td>Per 1&#x000a0;ng/ml</td><td>-0.17</td><td>-0.26 to -0.08**</td><td/><td/></tr><tr><td>&#x02003;Troponin T</td><td>&#x02264; 0.05&#x000a0;ng/ml</td><td>-9.54</td><td>-15.60 to -3.48**</td><td/><td/></tr><tr><td>&#x02003;NT-proBNP</td><td>&#x02264; 651.9&#x000a0;pg/ml</td><td>-6.05</td><td>-12.11 to 0.01*</td><td>-6.33</td><td>-12.40 to -0.26*</td></tr><tr><td>&#x02003;IL-6</td><td>Per 1&#x000a0;pg/ml</td><td>-0.19</td><td>-0.38 to -0.01*</td><td/><td/></tr><tr><td colspan="6">
<bold>SF-36 Vitality</bold>
</td></tr><tr><td>&#x02003;Female</td><td>Male</td><td>-5.73</td><td>-9.88 to -1.58**</td><td/><td/></tr><tr><td>&#x02003;Urea Reduction Ratio</td><td>&#x02264; 60%</td><td>8.58</td><td>3.52 to 13.64**</td><td>6.33</td><td>0.48 to 12.17*</td></tr><tr><td>&#x02003;White Blood Cells</td><td>&#x02264; 8.1 &#x000d7; 10<sup>9</sup>/L</td><td>-6.76</td><td>-11.62 to -1.91**</td><td/><td/></tr><tr><td>&#x02003;Leptin</td><td>Per 1&#x000a0;ng/ml</td><td>-0.09</td><td>-1.17 to -0.01*</td><td/><td/></tr><tr><td>&#x02003;C-reactive protein</td><td>Per 1&#x000a0;mg/L</td><td>-0.18</td><td>-0.35 to -0.00*</td><td/><td/></tr><tr><td>
<bold>FACIT Fatigue</bold>
</td><td/><td/><td/><td/><td/></tr><tr><td>&#x02003;Female</td><td>Male</td><td>-5.00</td><td>-8.26 to -1.73**</td><td/><td/></tr><tr><td>&#x02003;Body Mass Index</td><td>Per 1&#x000a0;kg/m<sup>2</sup>
</td><td>-0.30</td><td>-0.60 to 0.00*</td><td/><td/></tr><tr><td>&#x02003;Diabetes</td><td>No Diabetes</td><td>-5.07</td><td>-9.40 to -0.73*</td><td/><td/></tr><tr><td>&#x02003;Urea Reduction Rate</td><td>&#x02264; 60%</td><td>6.75</td><td>3.04 to 10.47**</td><td>5.61</td><td>1.42 to 9.81**</td></tr><tr><td>&#x02003;Leptin</td><td>Per 1&#x000a0;ng/ml</td><td>-0.10</td><td>-0.17 to -0.04**</td><td/><td/></tr></tbody></table><table-wrap-foot><p>*p&#x02009;&#x02264;&#x02009;0.05; **p&#x02009;&#x02264;&#x02009;0.01.</p><p>Unadjusted B coefficient was calculated using univariate linear regression (column 3 and 4).</p><p>Adjusted B coefficient was calculated using multiple linear regression to identify the significant and independent predictors (column 5 and 6).</p></table-wrap-foot></table-wrap></p></sec><sec id="Sec13"><title>Associations with change in HRQOL</title><p>Table&#x000a0;
<xref rid="Tab3" ref-type="table">3</xref> shows the significant univariate and multivariate associations for both short-term (24&#x000a0;weeks) and long-term (48 and 96&#x000a0;weeks) change in HRQOL for the 3 domains of interest. High troponin T levels at baseline were significantly and independently associated with decrease in SF-36 physical function at 48&#x000a0;weeks, decrease in SF-36 vitality at 96&#x000a0;weeks and decrease in FACIT fatigue at 24&#x000a0;weeks, independent of other variables significantly associated with the outcome. In a second multivariate model high troponin T levels were significantly associated with deterioration in physical function at 24, 48, and 96&#x000a0;weeks, decrease in vitality at 96&#x000a0;weeks, and decrease in fatigue at 24&#x000a0;weeks, independent of age, sex, diabetes and baseline HRQOL score (Table&#x000a0;
<xref rid="Tab4" ref-type="table">4</xref>). Examination of the unadjusted and adjusted B coefficients (Table&#x000a0;
<xref rid="Tab4" ref-type="table">4</xref>) suggest consistent impact of baseline troponin T levels on change in HRQOL. General linear models for repeated measures demonstrated that high troponin T levels were significantly associated with decrease in physical function scores (p&#x02009;&#x0003c;&#x02009;0.001), decrease in vitality of borderline significance (p&#x02009;=&#x02009;0.06), decrease in fatigue scores (p&#x02009;=&#x02009;0.04).<table-wrap id="Tab3"><label>Table 3</label><caption><p>
<bold>Significant associations between baseline clinical variables and biomarkers and change in short-term and long-term HRQOL scores, using univariate and multivariate analysis</bold>
</p></caption><table frame="hsides" rules="groups"><thead><tr><th>Characteristic</th><th>Reference</th><th>Unadjusted B coefficient</th><th>95% C.I.</th><th>Adjusted B coefficient</th><th>95% C.I.</th></tr></thead><tbody><tr><td colspan="6">
<bold>SF-36 Vitality</bold>
</td></tr><tr><td>Change at 24 wks</td><td/><td/><td/><td/><td/></tr><tr><td>&#x02003;High Hb Group</td><td>Low Hb Group</td><td>5.09</td><td>1.16 to 9.03*</td><td>5.11</td><td>1.07 to 9.14*</td></tr><tr><td>&#x02003;Platelet Count</td><td>&#x02264; 260 &#x000d7; 10<sup>9</sup>/L</td><td>-5.00</td><td>-9.63 to -0.38*</td><td>-4.99</td><td>-9.58 to -0.40*</td></tr><tr><td>Change at 48 wks</td><td/><td/><td/><td/><td/></tr><tr><td>&#x02003;Urea reduction ratio</td><td>&#x02264; 60%</td><td>-6.97</td><td>-12.22 to -1.72**</td><td>-7.06</td><td>-12.35 to 1.77**</td></tr><tr><td>&#x02003;Serum calcium</td><td>&#x02264; 2.42&#x000a0;mmol/L</td><td>5.34</td><td>0.94 to 9.73*</td><td>6.18</td><td>1.62 to 10.74**</td></tr><tr><td>&#x02003;Platelet count</td><td>&#x02264; 260 &#x000d7; 10<sup>9</sup>/L</td><td>-5.93</td><td>-10.67 to -1.18*</td><td>-5.01</td><td>-9.84 to -0.18*</td></tr><tr><td>&#x02003;Epo dose</td><td>&#x02264; 6000 U/wk</td><td>5.25</td><td>1.07 to 9.43*</td><td>5.73</td><td>1.53 to 9.93**</td></tr><tr><td>Change at 96 wks</td><td/><td/><td/><td/><td/></tr><tr><td>&#x02003;Fractional shortening</td><td>Per 1%</td><td>-0.32</td><td>-0.62 to -0.02*</td><td/><td/></tr><tr><td>&#x02003;Troponin T</td><td>&#x02264; 0.051&#x000a0;ng/ml</td><td>-7.55</td><td>-14.18 to -0.91*</td><td>-7.09</td><td>-13.73 to -0.46*</td></tr><tr><td colspan="6">
<bold>SF-36 Physical functioning</bold>
</td></tr><tr><td>Change at 24 wks</td><td/><td/><td/><td/><td/></tr><tr><td>&#x02003;Left Ventricular Mass Index</td><td>Per 1&#x000a0;g/m<sup>2</sup>
</td><td>-0.06</td><td>-0.12 to -0.00*</td><td/><td/></tr><tr><td>&#x02003;Serum Calcium</td><td>&#x02264; 2.42&#x000a0;mmol/L</td><td>4.25</td><td>0.02 to 8.47*</td><td/><td/></tr><tr><td>&#x02003;Platelet Count</td><td>&#x02264; 260 &#x000d7; 10<sup>9</sup>/L</td><td>-5.54</td><td>-9.95 to -1/13</td><td>-5.93</td><td>-10.37 to -1.50**</td></tr><tr><td>Change at 48 wks</td><td/><td/><td/><td/><td/></tr><tr><td>&#x02003;Serum Calcium</td><td>&#x02264; 2.42&#x000a0;mmol/L</td><td>6.63</td><td>1.61 to 11.66**</td><td>6.00</td><td>0.39 to 11.62*</td></tr><tr><td>&#x02003;Troponin T</td><td>&#x02264; 0.051&#x000a0;ng/ml</td><td>-6.40</td><td>-12.62 to -0.18*</td><td>-6.70</td><td>-12.93 to -0.47*</td></tr><tr><td>Change at 96 wks</td><td/><td/><td/><td/><td/></tr><tr><td>&#x02003;Diabetes</td><td>No Diabetes</td><td>-7.28</td><td>-14.07 to -0.49*</td><td>-8.84</td><td>-16.61 to -1.07*</td></tr><tr><td>&#x02003;Troponin T</td><td>&#x02264; 0.051&#x000a0;ng/ml</td><td>-9.43</td><td>-16.44 to -2.42**</td><td/><td/></tr><tr><td>
<bold>FACIT Fatigue</bold>
</td><td/><td/><td/><td/><td/></tr><tr><td>Change at 24 wks</td><td/><td/><td/><td/><td/></tr><tr><td>&#x02003;Lactase dehydrogenase</td><td>Per 1 U/L</td><td>-0.05</td><td>-0.09 to -0.00*</td><td/><td/></tr><tr><td>&#x02003;White blood cells</td><td>&#x02264; 8.1 &#x000d7; 10<sup>9</sup>/L</td><td>-4.32</td><td>-8.19 to -0.46*</td><td/><td/></tr><tr><td>&#x02003;Troponin T</td><td>&#x02264; 0.051&#x000a0;ng/ml</td><td>-5.38</td><td>-9.37 to -1.38**</td><td>-4.91</td><td>-9.09 to -0.74*</td></tr><tr><td>Change at 48 wks</td><td/><td/><td/><td/><td/></tr><tr><td>&#x02003;Serum creatinine</td><td>Per 1 umol/L</td><td>0.01</td><td>0.00 to 0.02**</td><td>0.01</td><td>0.00 to 0.02*</td></tr><tr><td>&#x02003;Platelet Count</td><td>&#x02264; 260 &#x000d7; 10<sup>9</sup>/L</td><td>-5.06</td><td>-9.20 to -0.93*</td><td>-4.78</td><td>-8.92 to -0.63*</td></tr><tr><td>Change at 96 wks</td><td/><td/><td/><td/><td/></tr><tr><td>&#x02003;Epo Dose</td><td>&#x02264; 6000 U/wk</td><td>-5.11</td><td>-9.92 to -0.31*</td><td/><td/></tr></tbody></table><table-wrap-foot><p>*p&#x02009;&#x02264;&#x02009;0.05; **p&#x02009;&#x02264;&#x02009;0.01.</p><p>Unadjusted B coefficient was calculated using univariate linear regression (column 3 and 4).</p><p>Adjusted B coefficient was calculated using multiple linear regression to identify the significant and independent predictors (column 5 and 6).</p></table-wrap-foot></table-wrap><table-wrap id="Tab4"><label>Table 4</label><caption><p>
<bold>The unadjusted and adjusted B coefficients for baseline Troponin T levels and baseline HRQOL scores and change in these scores over time, using univariate and multivariate analysis</bold>
</p></caption><table frame="hsides" rules="groups"><thead><tr><th/><th>Unadjusted B</th><th>p value</th><th>Adjusted B*</th><th>p value*</th><th>Adjusted B**</th><th>p value**</th></tr></thead><tbody><tr><td>
<bold>SF-36 Physical functioning</bold>
</td><td/><td/><td/><td/><td/><td/></tr><tr><td>&#x02003;Baseline</td><td>-9.54</td><td>0.002</td><td>-5.92</td><td>0.071</td><td/><td/></tr><tr><td>&#x02003;Change at 24 wks</td><td>-4.13</td><td>0.111</td><td/><td/><td>-6.02</td><td>0.018</td></tr><tr><td>&#x02003;Change at 48 wks</td><td>-6.40</td><td>0.044</td><td>-6.70</td><td>0.035</td><td>-8.09</td><td>0.008</td></tr><tr><td>&#x02003;Change at 96 wks</td><td>-9.43</td><td>0.009</td><td>-7.60</td><td>0.056</td><td>-8.42</td><td>0.015</td></tr><tr><td>
<bold>SF-36 Vitality</bold>
</td><td/><td/><td/><td/><td/><td/></tr><tr><td>&#x02003;Baseline</td><td>-1.56</td><td>0.571</td><td/><td/><td/><td/></tr><tr><td>&#x02003;Change at 24 wks</td><td>-3.46</td><td>0.182</td><td/><td/><td>-3.23</td><td>NS</td></tr><tr><td>&#x02003;Change at 48 wks</td><td>-1.36</td><td>0.633</td><td/><td/><td>-1.36</td><td>NS</td></tr><tr><td>&#x02003;Change at 96 wks</td><td>-7.55</td><td>0.026</td><td>-7.09</td><td>0.036</td><td>-7.10</td><td>0.037</td></tr><tr><td>
<bold>FACIT Fatigue</bold>
</td><td/><td/><td/><td/><td/><td/></tr><tr><td>&#x02003;Baseline</td><td>-1.58</td><td>0.465</td><td/><td/><td/><td/></tr><tr><td>&#x02003;Change at 24 wks</td><td>-5.38</td><td>0.008</td><td>-4.91</td><td>0.021</td><td>-5.95</td><td>0.002</td></tr><tr><td>&#x02003;Change at 48 wks</td><td>-3.89</td><td>0.093</td><td/><td/><td>-4.22</td><td>NS</td></tr><tr><td>&#x02003;Change at 96 wks</td><td>-5.46</td><td>0.057</td><td>-6.19</td><td>0.035</td><td>-4.56</td><td>NS</td></tr></tbody></table><table-wrap-foot><p>*Adjusted for other variables with p&#x02009;&#x02264;&#x02009;0.05.</p><p>**Adjusted for age, sex, diabetes status and baseline QoL score.</p><p>Unadjusted B coefficient was calculated using univariate linear regression.</p><p>Adjusted B coefficient was calculated using multivariate linear regression.</p></table-wrap-foot></table-wrap></p><p>Baseline NT-proBNP levels were not predictive of change in HRQOL (Additional file
<xref rid="MOESM1" ref-type="media">1</xref>: Table S2), nor were biomarkers of inflammation (CRP and ILS) or leptin. Additional file
<xref rid="MOESM1" ref-type="media">1</xref>: Table S3 shows the results from analysis of the other SF-36 domains, which were not pre-specified.</p></sec><sec id="Sec14"><title>Clinical associations with baseline Troponin T</title><p>Table&#x000a0;
<xref rid="Tab5" ref-type="table">5</xref> shows the significant univariate and multivariate associations between high troponin T levels at baseline and baseline clinical characteristics and biomarkers. The independent and significant predictors of high levels were male sex, older age, diabetes, high lactic dehydrogenase and high NT-proBNP levels.<table-wrap id="Tab5"><label>Table 5</label><caption><p>
<bold>Significant associations between baseline Troponin T levels and baseline clinical characteristics, using univariate and multivariate analysis</bold>
</p></caption><table frame="hsides" rules="groups"><thead><tr><th>Characteristic</th><th>Reference</th><th>Unadjusted B coefficient</th><th>95% C.I.</th><th>Adjusted B coefficient</th><th>95% C.I.</th></tr></thead><tbody><tr><td>Sex</td><td>Male</td><td>0.52</td><td>0.33 to 0.82**</td><td>0.38</td><td>0.22 to 0.67***</td></tr><tr><td>Age</td><td>Per 1&#x000a0;year</td><td>1.03</td><td>1.01 to 1.04**</td><td>1.02</td><td>1.00 to 1.04*</td></tr><tr><td>Diabetes</td><td>No Diabetes</td><td>4.59</td><td>2.81 to 7.48***</td><td>4.62</td><td>2.55 to 8.38***</td></tr><tr><td>LV Mass Index</td><td>1&#x000a0;g/m<sup>2</sup>
</td><td>1.01</td><td>1.01 to 1.02***</td><td/><td/></tr><tr><td>Hb</td><td>&#x02264; 11.1&#x000a0;g/dL</td><td>0.52</td><td>0.33 to 0.80**</td><td/><td/></tr><tr><td>Serum Albumin</td><td>&#x02264; 40&#x000a0;g/L</td><td>0.56</td><td>0.36 to 0.88*</td><td/><td/></tr><tr><td>Lactate Dehydrogenase</td><td>1 U/L</td><td>1.015</td><td>1.01 to 1.02***</td><td>1.01</td><td>1.00 to 1.02*</td></tr><tr><td>Potassium</td><td>1&#x000a0;mmol/L</td><td>1.36</td><td>1.03 to 1.79*</td><td/><td/></tr><tr><td>White Blood Cells</td><td>&#x02264; 8.1 &#x000d7; 10<sup>9</sup>/L</td><td>1.84</td><td>1.15 to 2.95*</td><td/><td/></tr><tr><td>Platelet Count</td><td>&#x02264; 260 &#x000d7; 10<sup>9</sup>/L</td><td>1.73</td><td>1.09 to 2.75*</td><td/><td/></tr><tr><td>NT-proBNP</td><td>&#x02264; 651.9&#x000a0;pg/ml</td><td>4.00</td><td>2.55 to 6.28***</td><td>3.53</td><td>2.04 to 6.13***</td></tr></tbody></table><table-wrap-foot><p>*p&#x02009;&#x02264;&#x02009;0.05; **p&#x02009;&#x02264;&#x02009;0.01; ***p&#x02009;&#x02264;&#x02009;0.001.</p><p>Unadjusted B coefficient was calculated using univariate linear regression (column 3 and 4).</p><p>Adjusted B coefficient was calculated using multivariate linear regression to identify the significant and independent predictors (column 5 and 6).</p></table-wrap-foot></table-wrap></p></sec></sec><sec id="Sec15" sec-type="discussion"><title>Discussion</title><p>The major conclusions in this paper were that in new hemodialysis patients without symptomatic cardiac disease:<list list-type="order"><list-item><p>HRQOL scores for physical function, vitality and fatigue were closer to those for the general population than for unselected hemodialysis patients, and on average changed little over 2&#x000a0;years of follow-up.</p></list-item><list-item><p>troponin T levels were elevated at baseline in a substantial minority of patients, and high values were significantly associated with high NT-proBNP levels independent of age, sex and diabetes.</p></list-item><list-item><p>high troponin T levels at baseline were significantly associated with decrease in physical function, vitality and fatigue, whereas NT pro-BNP levels were not.</p></list-item></list></p><p>The mean score in the general population for SF-36 physical function was 86 and for dialysis patients 41, (
[<xref ref-type="bibr" rid="CR12">12</xref>, <xref ref-type="bibr" rid="CR6">6</xref>]), whereas in our patients without symptomatic cardiac disease the score was 67 (
[<xref ref-type="bibr" rid="CR5">5</xref>]). For SF-36 vitality the comparable scores were 66, 43 and 58, and for FACIT fatigue the mean score in the general population was 80, in diabetic CKD patients 30 (
[<xref ref-type="bibr" rid="CR13">13</xref>]) and in our group 70. Clearly the presence of symptomatic cardiac disease is associated with HRQOL in dialysis patients. The current paper demonstrates that in dialysis patients without symptomatic cardiac disease at baseline few biomarkers were consistently associated with the deterioration in quality of life scores, but cardiac damage revealed by high Troponin T levels was associated with deterioration. It is important to note that the associations between change in HRQOL scores and high troponin T levels were not confounded by the prior occurrence of symptomatic heart failure or ischemic heart disease, or by the presence of LV dysfunction defined by a high LV volume. The fact that this group was relatively healthy is confirmed by the observation of an annual mortality of 5%, substantially lower than that in unselected hemodialysis patients (
[<xref ref-type="bibr" rid="CR9">9</xref>]).</p><p>In the study by Apple et al. (
[<xref ref-type="bibr" rid="CR14">14</xref>]) using the 99th percentile of a healthy reference population to define an elevated troponin T level, 82% of unselected asymptomatic hemodialysis patients had a level above this value ( &#x0003e; 0.01&#x000a0;ng/ml). In our study the interquartile range was 0.01 to 0.05&#x000a0;ng/ml. It is likely that elevated troponin T levels in dialysis patients reflects not only myocardial injury and ischemia but also myocardial fibrosis (
[<xref ref-type="bibr" rid="CR15">15</xref>]). A meta-analysis suggested that an elevated troponin T&#x02009;&#x0003e;&#x02009;0.1&#x000a0;ng/ml can identify a subgroup of dialysis patients with poor survival and higher risk of death (
[<xref ref-type="bibr" rid="CR16">16</xref>]). In a previous paper we reported that higher troponin T levels were predictive of subsequent cardiovascular events or death in our selected cohort, but that this association was not independent of age, diabetes, systolic blood pressure or NT-proBNP levels (
[<xref ref-type="bibr" rid="CR8">8</xref>]). The current paper lends support to the belief that high troponin levels are not innocuous, and that they are associated with deterioration in the physical domains of HRQOL. Whether this effect is mediated via the development of subsequent cardiac events which cause a decrease in HRQOL or by the degree of myocardial injury present at baseline is difficult to determine. The fact that high Troponin T levels were associated with lower HRQOL scores at baseline and after short-term follow-up suggests that the latter hypothesis is tenable, particularly as only 4% of cases developed a cardiovascular/death event by six months (myocardial infarction, myocardial ischemia, angina pectoris, cardiac failure, pulmonary edema, cerebellar infarction, cerebral hemorrhage, cerebral vascular disorder, or death) (
[<xref ref-type="bibr" rid="CR8">8</xref>]). Whether this interpretation is correct requires further investigation.</p><p>BNP or NT-proBNP is a cardiac biomarker reflecting LV wall stress that may occur secondary to volume expansion, pressure overload and increased wall tension (
[<xref ref-type="bibr" rid="CR15">15</xref>]). In our previous paper NT-proBNP in this selected group was an independent predictor of baseline LVMI, of increase in LVMI over time, and of the subsequent occurrence of cardiovascular events or death (
[<xref ref-type="bibr" rid="CR8">8</xref>]). Although higher BNP levels may be associated with left ventricular hypertrophy and with systolic dysfunction, in stable hemodialysis patients with normal LV function on echocardiography high BNP levels are likely the result of blood volume expansion and decrease with reduction in post dialysis &#x0201c;dry&#x0201d; weight (
[<xref ref-type="bibr" rid="CR17">17</xref>]). In the current paper, high BNP levels were not associated with a decrease HRQOL in the short-term or the long-term.</p><p>Limitations of the study include: 1. the study from which the data originated was not designed to evaluate the impact of cardiac biomarkers on HRQOL. 2. It was not possible to confirm that baseline Troponin T levels were predictive of HRQOL independent of subsequent cardiac events. However the group studied limited confounding induced by the presence of symptomatic cardiac disease and of echocardiographic systolic dysfunction. 3. It is possible that patients who did not have repeat measurements of HRQOL may be systematically different but this would likely lead to underestimate of the true association between the biomarkers and HRQOL.</p></sec><sec id="Sec16" sec-type="conclusions"><title>Conclusion</title><p>We conclude that in a group of patients without prior symptomatic cardiac disease at baseline or without a dilated LV, elevated troponin T levels, but not elevated BNP levels, on starting hemodialysis are associated with deterioration in the physical domains of HRQOL.</p></sec><sec sec-type="supplementary-material"><title>Electronic supplementary material</title><sec id="Sec17"><supplementary-material content-type="local-data" id="MOESM1"><media xlink:href="40697_2014_15_MOESM1_ESM.docx"><caption><p>Additional file 1: Table S1: Significant associations between baseline clinical variables and biomarkers and six baseline SF-36 HRQOL domains not pre-specified. <bold>Table S2.</bold> The unadjusted and adjusted B coefficients for baseline NT pro-BNP levels and baseline HRQOL scores and changes in these scores over time. <bold>Table S3.</bold> Significant associations between baseline clinical variables and biomarkers for change in six baseline SF-36 HRQOL domains not pre-specified, using univariate and multivariate analysis. (DOCX 21 KB)</p></caption></media></supplementary-material></sec></sec></body><back><fn-group><fn><p><bold>Competing interest</bold></p><p>P.S.P. has received research support and is an academic advisor to companies that make erythropoietin products &#x02013; Ortho Biotech, Amgen, and Roche. P.S.P. declares that he had full access to all of the data in the study and had final responsibility for the decision to submit for publication. R.N.F. has received research support and honoraria from Ortho Biotech.</p></fn><fn><p><bold>Authors&#x02019; contributions</bold></p><p>PSP and RNF the co-principal investigators, designed the trial, applied for funding to Johnson and Johnson, coordinated the study and wrote the reports. EWR performed the cardiac biomarker tests in collaboration with BMC CEW. performed the statistical analysis and contributed to the first draft of this manuscript. All authors read and approved the final manuscript.</p></fn></fn-group><ref-list id="Bib1"><title>References</title><ref id="CR1"><label>1.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lowrie</surname><given-names>EG</given-names></name><name><surname>Curtin</surname><given-names>RB</given-names></name><name><surname>LePain</surname><given-names>N</given-names></name><name><surname>Schatell</surname><given-names>D</given-names></name></person-group><article-title>Medical outcomes study short form-36: A consistent and powerful predictor of morbidity and mortality in dialysis patients</article-title><source>Am J Kidney Dis</source><year>2003</year><volume>41</volume><fpage>1286</fpage><lpage>1292</lpage><pub-id pub-id-type="doi">10.1016/S0272-6386(03)00361-5</pub-id><pub-id pub-id-type="pmid">12776282</pub-id></element-citation></ref><ref id="CR2"><label>2.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lopes</surname><given-names>AA</given-names></name><name><surname>Bragg-Gresham</surname><given-names>JL</given-names></name><name><surname>Satayathum</surname><given-names>S</given-names></name><name><surname>McCullough</surname><given-names>K</given-names></name><name><surname>Pifer</surname><given-names>T</given-names></name><name><surname>Goodkin</surname><given-names>DA</given-names></name><name><surname>Mapes</surname><given-names>DL</given-names></name><name><surname>Young</surname><given-names>EW</given-names></name><name><surname>Wolfe</surname><given-names>RA</given-names></name><name><surname>Held</surname><given-names>PJ</given-names></name><name><surname>Port</surname><given-names>FK</given-names></name></person-group><article-title>Worldwide Dialysis Outcomes and Practice Patterns Study Committee: Health-related quality of life and associated outcomes among hemodialysis patients of different ethnicities in the United States: The Dialysis Outcomes and Practice Patterns Study (DOPPS)</article-title><source>Am J Kidney Dis</source><year>2003</year><volume>41</volume><fpage>605</fpage><lpage>615</lpage><pub-id pub-id-type="doi">10.1053/ajkd.2003.50122</pub-id><pub-id pub-id-type="pmid">12612984</pub-id></element-citation></ref><ref id="CR3"><label>3.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kalantar-Zadeh</surname><given-names>K</given-names></name><name><surname>Kopple</surname><given-names>JD</given-names></name><name><surname>Block</surname><given-names>G</given-names></name><name><surname>Humphreys</surname><given-names>MH</given-names></name></person-group><article-title>Association among SF36 quality of life measures and nutrition, hospitalization, and mortality in hemodialysis</article-title><source>J Am Soc Nephrol</source><year>2001</year><volume>12</volume><fpage>2797</fpage><lpage>2806</lpage><pub-id pub-id-type="pmid">11729250</pub-id></element-citation></ref><ref id="CR4"><label>4.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Spiegel</surname><given-names>BMR</given-names></name><name><surname>Melmed</surname><given-names>G</given-names></name><name><surname>Robbins</surname><given-names>S</given-names></name><name><surname>Esrailian</surname><given-names>E</given-names></name></person-group><article-title>Biomarkers and health-related quality of life in end-stage renal disease: a systematic review</article-title><source>Clin J Am Soc Nephrol</source><year>2008</year><volume>3</volume><fpage>1759</fpage><lpage>1768</lpage><pub-id pub-id-type="doi">10.2215/CJN.00820208</pub-id><pub-id pub-id-type="pmid">18832106</pub-id></element-citation></ref><ref id="CR5"><label>5.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Foley</surname><given-names>RN</given-names></name><name><surname>Curtis</surname><given-names>BM</given-names></name><name><surname>Parfrey</surname><given-names>PS</given-names></name></person-group><article-title>Erythropoietin therapy, hemoglobin targets, and quality of life in healthy hemodialysis patients: a randomized trial</article-title><source>Clin J Am Soc Nephrol</source><year>2009</year><volume>4</volume><fpage>726</fpage><lpage>733</lpage><pub-id pub-id-type="doi">10.2215/CJN.04950908</pub-id><pub-id pub-id-type="pmid">19339412</pub-id></element-citation></ref><ref id="CR6"><label>6.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fukuhara</surname><given-names>S</given-names></name><name><surname>Lopes</surname><given-names>AA</given-names></name><name><surname>Bragg-Gresham</surname><given-names>JL</given-names></name><name><surname>Kurokawa</surname><given-names>K</given-names></name><name><surname>Mapes</surname><given-names>DL</given-names></name><name><surname>Akizawa</surname><given-names>T</given-names></name><name><surname>Bommer</surname><given-names>J</given-names></name><name><surname>Canaud</surname><given-names>BJ</given-names></name><name><surname>Port</surname><given-names>FK</given-names></name><name><surname>Held</surname><given-names>PJ</given-names></name></person-group><article-title>Worldwide Dialysis Outcomes and Practice Patterns Study: Worldwide Dialysis Outcomes and Practice patterns Study: Health-related quality of life among dialysis patients on three continents &#x02013; The Dialysis Outcomes and Practice Patterns Study</article-title><source>Kidney Int</source><year>2003</year><volume>64</volume><fpage>1903</fpage><lpage>1910</lpage><pub-id pub-id-type="doi">10.1046/j.1523-1755.2003.00289.x</pub-id><pub-id pub-id-type="pmid">14531826</pub-id></element-citation></ref><ref id="CR7"><label>7.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Briggs</surname><given-names>AH</given-names></name><name><surname>Parfrey</surname><given-names>PS</given-names></name><name><surname>Khan</surname><given-names>N</given-names></name><name><surname>Tseng</surname><given-names>S</given-names></name><name><surname>Dehmel</surname><given-names>B</given-names></name><name><surname>Chertow</surname><given-names>GM</given-names></name><name><surname>Belozeroff</surname><given-names>V</given-names></name></person-group><article-title>Analyzing health-related quality of life in the EVOLVE trial: the joint impact of treatment and clinical events</article-title><source>(Abstract) J Am Soc Nephrol</source><year>2013</year><volume>24</volume><fpage>458A</fpage><lpage>459B</lpage></element-citation></ref><ref id="CR8"><label>8.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Foley</surname><given-names>RN</given-names></name><name><surname>Curtis</surname><given-names>BM</given-names></name><name><surname>Randell</surname><given-names>EW</given-names></name><name><surname>Parfrey</surname><given-names>PS</given-names></name></person-group><article-title>Left ventricular hypertrophy in new hemodialysis patients without symptomatic cardiac disease</article-title><source>Clin J Amer Soc Nephrol</source><year>2010</year><volume>5</volume><fpage>805</fpage><lpage>813</lpage><pub-id pub-id-type="doi">10.2215/CJN.07761109</pub-id><pub-id pub-id-type="pmid">20378644</pub-id></element-citation></ref><ref id="CR9"><label>9.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Parfrey</surname><given-names>PS</given-names></name><name><surname>Foley</surname><given-names>RN</given-names></name><name><surname>Wittreich</surname><given-names>BH</given-names></name><name><surname>Sullivan</surname><given-names>DJ</given-names></name><name><surname>Zagari</surname><given-names>MJ</given-names></name><name><surname>Frei</surname><given-names>D</given-names></name></person-group><article-title>Double-blind comparison of full and partial anemia correction in incident hemodialysis patients without symptomatic heart disease</article-title><source>J Am Soc Nephrol</source><year>2005</year><volume>16</volume><fpage>2180</fpage><lpage>2189</lpage><pub-id pub-id-type="doi">10.1681/ASN.2004121039</pub-id><pub-id pub-id-type="pmid">15901766</pub-id></element-citation></ref><ref id="CR10"><label>10.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hays</surname><given-names>RD</given-names></name><name><surname>Kallich</surname><given-names>JD</given-names></name><name><surname>Mapes</surname><given-names>DL</given-names></name><name><surname>Coons</surname><given-names>SJ</given-names></name><name><surname>Carter</surname><given-names>WB</given-names></name></person-group><article-title>Development of the Kidney Disease Quality of Life (KDQOL) instrument</article-title><source>Qual Life Res</source><year>1994</year><volume>3</volume><fpage>329</fpage><lpage>338</lpage><pub-id pub-id-type="doi">10.1007/BF00451725</pub-id><pub-id pub-id-type="pmid">7841967</pub-id></element-citation></ref><ref id="CR11"><label>11.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Webster</surname><given-names>K</given-names></name><name><surname>Cella</surname><given-names>D</given-names></name><name><surname>Yost</surname><given-names>K</given-names></name></person-group><article-title>The Functional assessment of chronic illness therapy (FACIT) measurement system: properties, applications, and interpretation</article-title><source>Health Q Life Outcomes</source><year>2003</year><volume>1</volume><fpage>79</fpage><lpage>86</lpage><pub-id pub-id-type="doi">10.1186/1477-7525-1-79</pub-id></element-citation></ref><ref id="CR12"><label>12.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hopman</surname><given-names>WM</given-names></name><name><surname>Towheed</surname><given-names>T</given-names></name><name><surname>Anastassiades</surname><given-names>T</given-names></name><name><surname>Tenenhouse</surname><given-names>A</given-names></name><name><surname>Poliquin</surname><given-names>S</given-names></name><name><surname>Berger</surname><given-names>C</given-names></name><name><surname>Joseph</surname><given-names>L</given-names></name><name><surname>Brown</surname><given-names>JP</given-names></name><name><surname>Murray</surname><given-names>TM</given-names></name><name><surname>Adachi</surname><given-names>JD</given-names></name><name><surname>Hanley</surname><given-names>DA</given-names></name><name><surname>Papadimitropoulos</surname><given-names>E</given-names></name></person-group><article-title>and the Canadian Multicentre Osteoporosis Study Research Group. Canadian normative data for the SF-36 health survey</article-title><source>Can Med Assoc J</source><year>2000</year><volume>163</volume><fpage>265</fpage><lpage>271</lpage><pub-id pub-id-type="pmid">10951722</pub-id></element-citation></ref><ref id="CR13"><label>13.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lewis</surname><given-names>EF</given-names></name><name><surname>Pfeffer</surname><given-names>MA</given-names></name><name><surname>Feng</surname><given-names>A</given-names></name><name><surname>Uno</surname><given-names>H</given-names></name><name><surname>McMurray</surname><given-names>JJV</given-names></name><name><surname>Toto</surname><given-names>R</given-names></name><name><surname>Gaudra</surname><given-names>SR</given-names></name><name><surname>Solomon</surname><given-names>SD</given-names></name><name><surname>Moustafa</surname><given-names>M</given-names></name><name><surname>MacDougall</surname><given-names>IC</given-names></name><name><surname>Locatelli</surname><given-names>F</given-names></name><name><surname>Parfrey</surname><given-names>PS</given-names></name></person-group><article-title>for the TREAT investigators. Darbopoietin alfa impact on health states in diabetes patients with kidney disease: a randomized trial</article-title><source>Clin J Am Soc Nephrol</source><year>2011</year><volume>6</volume><fpage>845</fpage><lpage>855</lpage><pub-id pub-id-type="doi">10.2215/CJN.06450710</pub-id><pub-id pub-id-type="pmid">21212421</pub-id></element-citation></ref><ref id="CR14"><label>14.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Apple</surname><given-names>FS</given-names></name><name><surname>Murakami</surname><given-names>MM</given-names></name><name><surname>Pearce</surname><given-names>LA</given-names></name><name><surname>Herzog</surname><given-names>CA</given-names></name></person-group><article-title>Predictive value of cardiac troponin I and T for subsequent death in end-stage renal disease</article-title><source>Circulation</source><year>2002</year><volume>106</volume><fpage>2941</fpage><lpage>2945</lpage><pub-id pub-id-type="doi">10.1161/01.CIR.0000041254.30637.34</pub-id><pub-id pub-id-type="pmid">12460876</pub-id></element-citation></ref><ref id="CR15"><label>15.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>AY-M</given-names></name><name><surname>Lam</surname><given-names>CW-K</given-names></name></person-group><article-title>The diagnostic utility of cardiac biomarkers in dialysis patients</article-title><source>Sem Dial</source><year>2012</year><volume>25</volume><fpage>388</fpage><lpage>396</lpage><pub-id pub-id-type="doi">10.1111/j.1525-139X.2012.01099.x</pub-id></element-citation></ref><ref id="CR16"><label>16.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Khan</surname><given-names>NA</given-names></name><name><surname>Hemmelgarn</surname><given-names>BR</given-names></name><name><surname>Tonelli</surname><given-names>M</given-names></name><name><surname>Thompson</surname><given-names>CR</given-names></name><name><surname>Levin</surname><given-names>A</given-names></name></person-group><article-title>Prognostic value of troponin T and I among asymptomatic patients with end-stage renal disease: a meta-analysis</article-title><source>Circulation</source><year>2005</year><volume>112</volume><fpage>3088</fpage><lpage>3096</lpage><pub-id pub-id-type="doi">10.1161/CIRCULATIONAHA.105.560128</pub-id><pub-id pub-id-type="pmid">16286604</pub-id></element-citation></ref><ref id="CR17"><label>17.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Parfrey</surname><given-names>PS</given-names></name></person-group><article-title>BNP in hemodialysis patients</article-title><source>Clin J Am Soc Nephrol</source><year>2010</year><volume>5</volume><fpage>954</fpage><lpage>955</lpage><pub-id pub-id-type="doi">10.2215/CJN.02710310</pub-id><pub-id pub-id-type="pmid">20507956</pub-id></element-citation></ref></ref-list></back></article>